Focal Segmental Glomerulosclerosis (FSGS) Market Will Likely Rise at a Solid 8.0% CAGR over the Course of the Forecast Period from 2017 to 2025
The focal segmental glomerulosclerosis (FSGS) market is highly competitive due to presence of numerous large players and presence of local players. Some of the key participants in the global market for focal segmental glomerulosclerosis (FSGS) are Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., and Retrophin, Inc. The global focal segmental glomerulosclerosis (FSGS) market will likely see continued changes in its contours with the successful launch of pipeline products in the next couple of years.
View full press release